NCT03521037View on ClinicalTrials.gov

Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

February 27, 2018

Primary Completion Date

September 27, 2019

Study Completion Date

February 24, 2021

Conditions
Neoplasms
Interventions
DRUG

Rucaparib camsylate

In Part I, eligible patients will receive a single oral dose of 600 mg rucaparib followed by intensive plasma PK sampling up to Day 7 (hour 144). In Part II, patients may continue to receive continuous oral rucaparib in 28 day cycles.

Trial Locations (6)

21-500

Wojewódzki Szpital Specjalistyczny w Białej Podlaskiej, Biała Podlaska

60-693

Med Polonia Sp. z o.o., Poznan

71-730

Zachodniopomorskie Centrum Onkologii w Szczecinie, Szczecin

02-681

BioVirtus Centrum Medyczne, Warsaw

831 01

Summit Clinical Research s.r.o., Bratislava

NE7 7DN

Northern Centre for Cancer Care, Newcastle upon Tyne

All Listed Sponsors
lead

pharmaand GmbH

INDUSTRY

NCT03521037 - Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor | Biotech Hunter | Biotech Hunter